Disitamab Vedotin not checked

RemeGen · RC48-ADC · RC48

FollowEvery change as it happens, and a Monday email
Stage
in China
Next date
Phase 3 trial completes
Trials
16 active
29 in total
Targets
—
None known yet

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
How it’s given
“Disitamab Vedotin: 2.5 mg/kg, IV, D1, Q2W; Tislelizumab: 200 mg, IV, D1, Q3W Oxaliplatin: 100 mg/m², IV, D1, Q3W; Capecitabine: 750 mg/m², po, BID, D1-D14, Q3W”In the company’s words, NCT06944496 on ClinicalTrials.gov
Tested for
Breast Cancer (5 trials), Gastric Cancer (3 trials), Gastric Carcinoma (2 trials), Gastroesophageal Junction Adenocarcinoma (2 trials), Urothelial Carcinoma, HER2-expressing, NMIBC, Cervical Cancer and 3 more
Main trialPhase 3
“This is a Phase 3, Open-Label, Multicenter, Randomised, Controlled Study designed to compare RC48-ADC in Combination With JS001 to Chemotherapy Alone in Previously Untreated HER2-Expressing Unresectable Locally Advanced or Metastatic Urothelial Carcinoma.”In the company’s words, NCT05302284 on ClinicalTrials.gov
Other names
RC48-ADC · DV · RC48

Other drugs for Breast Cancer

All 396 drugs for Breast Cancer

Coming up8

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials29

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 31 Dec 2026 A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma
Phase 3Recruiting 31 Dec 2027 A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2
Phase 3Not yet recruiting 15 May 2028 A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Phase 3Recruiting 30 Jun 2029 A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
Phase 2/3Active, not recruiting 10 Jul 2025 A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer
Phase 2/3Recruiting Dec 2026 DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
Phase 2Recruiting 31 Jan 2025 Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
Phase 2Recruiting 1 Jun 2025 To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer
Phase 2Recruiting 1 Dec 2025 RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects
Phase 2Recruiting Dec 2025 Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer
Phase 2Recruiting Jun 2026 DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer
Phase 2Recruiting 1 Oct 2026 Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer
Phase 2Recruiting 30 Jun 2027 A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer
Phase 1/2Not yet recruiting 1 Dec 2027 A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation
Phase 1/2Recruiting 15 Mar 2029 To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2
Phase 1Recruiting 16 Nov 2024 RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression
Phase 3Unknown 1 Dec 2024 A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression
Phase 2/3Unknown 31 Jul 2024 A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases
Phase 2Completed 1 Jun 2020 A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer Subjects With the Overexpression of HER2
Phase 2Completed 4 Mar 2021 A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer
Phase 2Completed 30 Sep 2022 A Study of RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial Cancer
Phase 2Unknown 3 Nov 2023 A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer
Phase 2Unknown 1 Jun 2024 A Study of RC48-ADC Combined With JS001 For Perioperative Treatment of Muscle-Invasive Bladder Cancer
Phase 2Unknown Oct 2024 A Study of RC48-ADC for the Treatment of HER2-expressing Gynecological Malignancies
Phase 2Unknown 30 Dec 2024 A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression)
Phase 2Withdrawn 20 Dec 2025 Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer
Phase 2Unknown Dec 2025 Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer
Phase 1/2Completed 31 Jul 2022 A Study of RC48-ADC in Subjects With Advanced Breast Cancer
Phase 1Unknown 30 May 2024 To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Disitamab Vedotin

Following is part of Solo: you see every change to Disitamab Vedotin the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in